Shamsa Ali, MD
Endocrinology, Diabetes & Metabolism · Warren, MINPI 1487780755
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by AstraZeneca at 36.1% of the total. Reporting peaked in 2019 at $11,410 and has fallen 76.8% since, to $2,644 in 2025. Among endocrinology, diabetes & metabolism clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 843 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$13K
- Merck$8K
- Medtronic$3K
- Novo Nordisk$2K
- AbbVie$1K
- Corcept Therapeutics$886
- plus $8K from 43 others
What the payments were for
- Speaking & faculty fees$18,58053%
- Travel & lodging$2,3557%
- Food & beverage$14,01340%
- Education$1400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$11,650
- STEGLATRO$7,055
- MINIMED 770G$1,900
- SOLIQUA 100/33$233
- Accurian$172
- MYCAPSSA$113
- GUARDIAN SENSOR (3)$112
- Ozempic$107
How this compares
$35,088 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 380 | $632,932 |
| TrulicityDulaglutide | 266 | $478,348 |
| KorlymMifepristone | 23 | $463,909 |
| JardianceEmpagliflozin | 379 | $418,917 |
| MounjaroTirzepatide | 172 | $253,408 |
| FarxigaDapagliflozin Propanediol | 190 | $232,628 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $74,808 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $69,846 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $46,415 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $45,942 |
| JanuviaSitagliptin Phosphate | 41 | $44,193 |
| KerendiaFinerenone | 31 | $38,737 |
| Novolog FlexpenInsulin Aspart | 125 | $35,633 |
| Humalog Kwikpen U-100Insulin Lispro | 54 | $35,518 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 143 | $32,853 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $848 | $751,410483 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,647 | $683,186437 claims |
| Corcept TherapeuticsKorlym | $886 | $463,90923 claims |
| Boehringer IngelheimJardiance | $341 | $418,917379 claims |
| AstraZenecaFarxiga | $12,654 | $232,628190 claims |
| MerckJanuvia | $7,574 | $44,19341 claims |
| BayerKerendia | $493 | $38,73731 claims |
| AbbVieSynthroid | $1,055 | $22,901245 claims |
| Johnson & JohnsonInvokana | $182 | $15,09811 claims |
| IBSA Pharma Inc.Tirosint | $223 | $11,60433 claims |
| Sanofi-aventis U.S. LLCLantus | $836 | $7,63238 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $314 | $7,628456 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
Other endocrinology, diabetes & metabolism in Warren
- Lowell SchmeltzFarmington Hills$1.3M
- George GrunbergerBloomfield Hills$931K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Jamal HammoudFlint$386K
- Abdulsalam Al KassabRochester Hills$351K
- Richard AuchusAnn Arbor$250K
- Eric LangerSterling Heights$213K
- Ashish VermaShelby Twp$179K
- Kara HoisingtonLansing$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.